Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics (RNTX)
NASDAQ:RNTX
RNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $7.42
Previous CloseN/A
VolumeN/A
Average Volume (3M)40.84K
Market Cap
$38.35M
Enterprise Value$104.02M
Total Cash (Recent Filing)$10.63M
Total Debt (Recent Filing)$5.34M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
May 07, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.11
Shares Outstanding21,665,941
10 Day Avg. Volume25,505
30 Day Avg. Volume40,838
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-874.08
Enterprise Value/Ebitda-3.53
Forecast
1Y Price Target
$8.00Price Target Upside370.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Rein Therapeutics News
---
Ownership Overview
10.18% Insiders
2.74% Mutual Funds
21.81% Other Institutional Investors
61.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.61 and its highest was $7.42 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $38.35M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 39 days.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.46.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 21,665,941 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
---
Rein Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (370.59% Upside)
$8.00 (370.59% Upside)
Insider Transactions
Bought Shares
Worth $897.6 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.46%
12-Months-Change
Fundamentals
Return on Equity
-54.95%
Trailing 12-Months
Asset Growth
712.80%
Trailing 12-Months
Company Description
Rein Therapeutics
Aileron Therapeutics, Inc. (ALRN) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to protect healthy cells from chemotherapy-induced damage while enhancing the anti-tumor effects of chemotherapy. The company operates within the biotechnology and pharmaceuticals sector, with its core product being ALRN-6924, a first-in-class dual MDM2/MDMX inhibitor designed to treat a wide range of cancers by targeting the p53 tumor suppressor pathway.
---
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(370.59% Upside)
Technical Analysis
Karyopharm Therapeutics
―
TG Therapeutics
―
Actinium Pharmaceuticals
―
Cellectar Biosciences
―
Best Analysts Covering RNTX
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-42.93%
reiterated a buy rating 12 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -42.93% per trade.
---